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Abstract Introduction: Two mutations in CYP1A2,
)164C ﬁ A (allele CYP1A2*F) and )3858G ﬁ A
(allele CYP1A2*C), aﬀecting the inducibility of the
enzyme, have been published. The aim of this study was
to develop a high throughput allelic discrimination assay
for these mutations in both saliva and blood and to
determine their frequency in Caucasians.
Methods: An allelic discrimination assay, based on the
ﬂuorogenic 5¢-nuclease activity (TaqMan), was devel-
oped for the two mutations. Genomic DNA extracted
from 17 saliva and 100 blood samples from Caucasians
was analysed.
Results and conclusions: For the )164C ﬁ A mutation,
we found an allelic frequency of 68% in the Caucasian
population, comparable with data published for Asians
and Caucasians. For the )3858G ﬁ A mutation, the
allele frequencywas only 2% inCaucasians, amuch lower
value than the ~25% reported in Asians (P<0.001). The
presented allelic discrimination allows fast and accurate
detection of these two mutations. Genotype calls were
100% identical for DNA from saliva and blood. Saliva is
easily accessible and represents an excellent alternative
to the traditionally used venous blood for genotyping.
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Introduction
To improve drug eﬀectiveness or reduce toxicity,
increasing importance is attributed to genotyping of
drug metabolising enzymes [1]. As a member of the
cytochrome P450 superfamily, CYP1A2 plays an
important role in the activation of carcinogens and in
the metabolism of many drugs [2, 3, 4, 5, 6, 7, 8, 9]. No
functional genetic polymorphism explaining the high
inter-individual variability of the enzyme activity has
been reported until now [10, 11, 12]. However, two
mutations associated with inducibility of CYP1A2 gene
expression have been described, namely the )164C ﬁ A
mutation in intron 1 (allele CYP1A2*F) and the
)3858G ﬁ A mutation in the precoding region (allele
CYP1A2*C) [13, 14, 15, 16, 17, 18]. It was suggested
that the )164C ﬁ A mutation in the CYP1A2 gene
might be in linkage with the )3858G ﬁ A mutation
[13]. The published methods to identify these mutations
are based on polymerase chain reaction—restriction
fragment length polymorphism (PCR-RFLP). The aim
of the present study was the development of a rapid
allelic discrimination technique for the identiﬁcation of
these mutations, to determine their prevalence in the
Caucasian population, and—because saliva is the pre-
ferred matrix for non-invasive CYP1A2 phenotyping
[19, 20]—to investigate the use of saliva as a source of
genomic DNA. This allows to combine CYP1A2
phenotyping and genotyping in the same matrix.
Methods
Subjects
Genomic DNA samples were from 100 Caucasians from Switzer-
land. Saliva samples were collected from Caucasian and Chinese
staﬀ members and students. Participants were investigated after
giving signed informed consent. This work was part of a larger
study on the inducibility of CYP1A2 activity, approved by the
ethics committee of the University Hospital Basel.
DNA isolation and mutation analysis
Genomic DNA was isolated from blood or saliva with the QIAamp
DNA Blood Kit (Qiagen, Basel, Switzerland) according to the
manufacturer’s recommendations for blood, and as described by
van Schie and Wilson for saliva [21].
Allelic discrimination using the 5¢-nuclease activity assay was
adapted to detect the )164C ﬁ A and )3858G ﬁ A mutations.
Primers and probes, designed using the Primer Express 1.5 software
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(Applied Biosystems, Rotkreuz, Switzerland), are shown in
Table 1. Probes for )164C ﬁ A are antisense, probes for the
)3858G ﬁ A mutation are minor groove binder (MGB) probes.
Probes were labelled with the ﬂuorophores FAM or VIC. Primers
were fromMicrosynth (Balgach, Switzerland), TaqMan probes and
Universal PCRMaster Mix were from Applied Biosystems. A 25-ll
total reaction volume was used and, post-PCR, the allelic speciﬁc
ﬂuorescence was measured on the ABI prism 7700 (Applied
Biosystems) using the Sequence Detection Systems 1.7 software
for allelic discrimination. The genotype calls were attributed
automatically.
PCRs with restriction analysis for the two mutations were
performed, using the published primers and restriction enzymes
[14, 15].
To validate the use of genomic DNA from saliva, DNA was
extracted from both blood and saliva of ten volunteers and the
presence of the two CYP1A2 mutations was compared.
Sequence analysis for verifying the )3858G ﬁ A mutation was
performed on 17 DNA samples by Microsynth (Balgach, Switzer-
land). In parallel to the 5¢-allelic discrimination assay, RFLP-PCR
was performed on ten saliva samples to validate the results of the
5¢-nuclease assay.
Statistical analysis
The allele frequency in our subjects is given together with the 95%
conﬁdence interval. Diﬀerences in allele frequencies between the
two populations were analysed with the v2 test. A P value <0.05
was considered statistically signiﬁcant. Statistical analysis was
performed with Statview.
Results
The 5¢-allelic discrimination method was adapted to
detect the )164C ﬁ A or )3858G ﬁ A mutations in
the CYP1A2 gene and over 100 DNA samples from
Caucasians were analysed.
Regarding the )3858G ﬁ A mutation, PCR-RFLP
on 20 Caucasian DNA samples did not reveal a homo-
zygote sample needed to establish the TaqMan allelic
discrimination method for this mutation. Sequencing
conﬁrmed the absence of the mutation in all these
samples. As the mutation was published to be present in
the Japanese and Chinese populations, we screened 14
Chinese volunteers and found four heterozygotes and
three homozygotes for the mutation. After establishing
the Taqman allelic discrimination method, four
)3858G ﬁ A mutations were detected in 100 Caucasian
DNA samples screened.
Considering the )164C ﬁ A mutation, nine subjects
with the )164C/C genotype were detected. Since, as
discussed above, the homozygous )3858A/A form was
not found, the combination with the )164C/C genotype
was also absent in our population.
Table 2 shows the allele frequencies for the two
mutations from our data and that published previously
[14, 15, 16, 17, 18, 22, 23]. The results show no diﬀer-
ence between Caucasian and Asian populations for the
)164C ﬁ A mutation, but a signiﬁcantly low frequency
of the )3858G ﬁ A mutation in Caucasians
(P<0.001).
The yield of DNA from 1 ml saliva varied from
5.5 lg to 46.2 lg (20.5±11.4 lg, mean±SD). PCR runs
revealed no disturbing interference when DNA origi-
nating from saliva was used. The allelic discrimination
method gave a 100% agreement of the results between
saliva and blood.
Table 1 Sequences and positions of primers, wild-type (WT) and mutant (MT) TaqMan probes and MGB probes are listed for mutations
)164C ﬁ A and )3858G ﬁ A. The polymorphic nucleotides in the probes are underlined. Positions are according to accession number
AF253322
Mutation Position Sequence
)164C ﬁ A 34725 Forward primer 5¢-GGCTCCTTTCCAGCTCTCAGA
)164C ﬁ A 34859 Reverse primer 5¢-TGATAAACACTGATGCGTGTTCTG
)164C ﬁ A 34770 WT probe (anti-sense) 5¢FAM-ATGCGTCCTGGGCCCACAGA-TAMRA
)164C ﬁ A 34769 MT probe (anti-sense) 5¢VIC-CATGCGTCCTGTGCCCACAGAG-TAMRA
)3858G ﬁ A 31034 Forward primer 5¢-GGAGTGCAGTGGTGCGATCT
)3858G ﬁ A 31133 Reverse primer 5¢-CACACCTGTAATTCCAGCTACTCG
)3858G ﬁ A 31073 WT probe (anti-sense) 5¢FAM-CCTCTCGGATTCAA-MGB
)3858G ﬁ A 31073 MT probe (anti-sense) 5¢VIC-CCTCTCAGATTCAAG-MGB
Table 2 Allele frequencies of CYP1A2 mutations in diﬀerent ethnic groups
Source Number of alleles Allele frequency )164C ﬁ A (95% CI*) Allele frequency )3858G ﬁ A (95% CI*)
Nakajima et al. 1999 [14] 232 – 0.23 (0.17–0.28)
Sachse et al. 1999 [15] 472 0.68 (0.63–0.71) –
Mihara et al. 2000 [22] 202 – 0.22 (0.16–0.27)
Han et al. 2001 [16] 278 0.67 (0.62–0.72) 0.25 (0.20–0.30)
Shimoda et al. 2002 [23] 80 0.70 (0.60–0.80) 0.24 (0.15–0.33)
Sachse et al. 2003 [18] 130 0.66 (0.58–0.74) 0.008 (0.00–0.02)
Hamdy et al. 2003 [17] 424 0.68 (0.64–0.72) 0.07 (0.04–0.09)
Present study 200 0.68 (0.62–0.74) 0.02 (0.01–0.03)
*95% CI, 95% conﬁdence interval
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Discussion
The methods published so far for the detection of the
)164C ﬁ A and )3858G ﬁ A mutations are PCR-
RFLP based [14, 15].
Allelic discrimination described here allows a high
throughput, a general need in genetic studies [24], and
reveals a high accuracy. As shown in the current and
previous investigations [25, 26], the method allows an
automated assignment of the genotype. The diﬀerentia-
tion of the genotypes can be optimised by the use of
MGB probes, resulting in a better clustering of the ﬂu-
orescence signals. Frequencies of the C and A allele for
the )164C ﬁ A mutation in our population were 32%
and 68%, respectively. These results are in good agree-
ment with frequencies found in Caucasians and in the
studies in Asian populations [13, 15, 16, 17, 18, 23]. For
the )3858G ﬁ A mutation, we found a frequency for
the G allele of 98%, whereas the mutant A allele rep-
resented only 2%. This is conﬁrmed by a recent publi-
cation, whereas in Asian populations frequencies are
reported in a narrow range between 22% and 25% for
the A allele [13, 14, 16, 18, 23]. Han et al. reported that
with the )3858A/A variant ()2964A/A in the original
publication) present, the )164C/A or )164C/C variants
(734C/A in the original publication) are absent. The
)3858A/A variant in combination with )164C alleles
would result in reduced inducibility of CYP1A2 and a
linkage of the )3858A/A with the )164A/A variant
would restore inducibility of CYP1A2. We could not
conﬁrm this hypothesis because of the absence of the
)3858A/A variant in our population of 100 Caucasians
analysed. The very low incidence of the )3858G ﬁ A
mutation in Caucasians suggests that this mutation has
no signiﬁcant inﬂuence on CYP1A2 activity, since the
frequency of slow CYP1A2 metabolisers is not diﬀerent
between Caucasians and Asians [27, 28, 29]. Thus, the
contribution of other genetic or environmental factors
seems to be more important for CYP1A2 activity. Since
the contributions of these two mutations to CYP1A2
activity were not very important in previous studies [14,
15, 16], further prospective studies in larger populations
are needed, analysing the relationship between induc-
ibility of CYP1A2 and the presence of the )164C ﬁ A
and )3858G ﬁ A mutations.
Although several publications report the use of sal-
iva, hair and ﬁngernails for genotyping [21, 30, 31, 32,
33], in the hospital setting genotyping is usually based
on invasive blood sampling. Since saliva is the preferred
matrix for non-invasive determination of the CYP1A2
phenotype by caﬀeine as a probe drug [19], we vali-
dated the use of saliva as a source of genomic DNA
instead of blood. This allows CYP1A2 phenotyping
and genotyping in one sample, obtained non-invasively.
The amount of DNA we have isolated from 1 ml of
saliva was suﬃcient for several PCR-based tests. Simi-
lar to blood, DNA isolated from saliva gave no inter-
ference in the consecutive PCR assays, indicating that
saliva could replace blood as a DNA source for
genotyping.
Conclusions
While the frequency of the )164C ﬁ A mutation in our
study is in agreement with published data for Cauca-
sians and Asians, the frequency of the )3858G ﬁ A
mutation is signiﬁcantly lower in Caucasians than
Asians. The use of 5¢-nuclease activity combined with
ﬂuorogenic probes allows fast and high throughput
allelic discrimination of these two mutations and gives
100% agreement with the PCR-RFLP method. Saliva is
a reliable and easily available source of genomic DNA
for genotyping.
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